Abstract

Purpose/objectives: Primary small cell esophageal carcinoma (SCEC) is a rare malignancy without an established treatment strategy. This study investigated the gene expression profile of SCEC and compared it with the expression profiles of small cell lung cancer (SCLC) and esophageal adeno/squamous carcinoma (EAC/ESCC).Materials/methods: All patients with SCEC, SCLC, and EAC/ESCC in the Surveillance, Epidemiology, and End Results (SEER) database 1973–2014 were included. Overall survival (OS) and prognostic analysis were conducted. De novo expression array analysis was performed on three pairs of frozen primary SCEC tissues and the corresponding normal samples from the institutional tissue bank using the Affymetrix HG U133 plus 2.0 Array. These data were complemented with public domain expression data sets from the Gene Expression Omnibus (GEO) repository using the same working platforms, which included primary SCLC, EAC/ESCC, and normal lung/esophagus specimens (series GSE30219 and GSE26886). After individual normalization, the primary tumors were submitted to statistical analysis (GeneSpring GX 13.0) to identify the differentially expressed genes (DEGs) relative to their paired normal tissues. Enrichments of genes categorized by function and gene interactions were analyzed by DAVID 6.8 and STRING 11.0, respectively.Results: The clinical outcomes of the patients with SCEC were significantly more worse than those with EAC/ESCC and SCLC in the SEER database. SCEC had more DEGs in common with SCLC than EAC/ESCC [829 vs. 450; false discovery rate (FDR) < 0.01; and fold change ≥2], leading to a stronger correlation between SCEC and SCLC (Pearson's correlation coefficient was 0.60 for SCEC vs. SCLC, 0.51 or 0.45 for SCEC vs. ESCC or EAC, and the coefficient was 0.73 for ESCC vs. EAC). Similar findings were obtained by principal component analysis (PCA) using all DEGs retrieved from these four groups. Functional annotation showed that a higher proportion of pathways and biological processes were common between SCEC and SCLC and were associated with the cell cycle (mitosis), DNA replication, telomere maintenance, DNA repair, and P53 and RB pathways (Benjamini p < 0.05). Compared with EAC/ESCC, SCEC shared more co-upregulated DEGs coding for the aforementioned common pathways with SCLC (584 vs. 155). In addition, SCEC and SCLC were found to have possessed overlapping gene-interactive networks, with centromere protein F (CENPF), never in mitosis gene A-related kinase 2 (NEK2), kinesin family member 11 (KIF11), thymopoietin (TMPO), and forkhead box protein M1 (FOXM1) as common skeletons centered by gene regulatory network (NUF2).Conclusions: This study is the first attempt to examine the genomic signatures of SCEC at the transcriptomic level and compare the expression profiles between SCEC, SCLC, and EAC/ESCC. Our preliminary data indicate that SCEC and SCLC display notably similar patterns of gene expression for mitosis and DNA repair. Further validation studies are warranted.

Highlights

  • Small cell carcinoma (SCC) is a highly aggressive malignancy that predominantly arises in the lung

  • Patients with small cell lung cancer (SCLC) accounted for the largest proportion (33,627, 52.7%), followed by EAC (16,573, 26.0%), ESCC (13,100, 20.5%), and small cell esophageal carcinoma (SCEC) (468, 0.7%)

  • Compared with EAC/ESCC, SCEC shared more co-upregulated differentially expressed genes (DEGs) coding for the aforementioned common pathways with SCLC (584 vs. 155; Figure 3)

Read more

Summary

Introduction

Small cell carcinoma (SCC) is a highly aggressive malignancy that predominantly arises in the lung. Primary small cell esophageal carcinoma (SCEC) is the most common extrapulmonary SCC (∼2%), with a reported incidence rate of 0.05–3.1% among all esophageal neoplasms [1,2,3]. Due to a lack of prospective clinical trials or cell line experimental data, a consensus on treatment strategies for patients with SCEC has not been reached [4, 5]. Previous studies have indicated similarities in pathology and clinical manifestations between SCEC and small cell lung cancer (SCLC), and patients with SCEC are staged and treated following the well-established therapeutic strategies for SCLC [4, 6] patients with SCEC have a significantly worse prognosis than those with esophageal adeno/squamous carcinoma (EAC/ESCC) and SCLC. More effective and precise therapeutic strategies for SCEC are urgently needed [7,8,9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call